List of Excipients in Branded Drug CYTALUX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
On Target Laboratories Inc	CYTALUX	pafolacianine injection	81052-138	HYDROCHLORIC ACID	2033-08-26
On Target Laboratories Inc	CYTALUX	pafolacianine injection	81052-138	POTASSIUM PHOSPHATE, MONOBASIC	2033-08-26
On Target Laboratories Inc	CYTALUX	pafolacianine injection	81052-138	SODIUM CHLORIDE	2033-08-26
On Target Laboratories Inc	CYTALUX	pafolacianine injection	81052-138	SODIUM HYDROXIDE	2033-08-26
On Target Laboratories Inc	CYTALUX	pafolacianine injection	81052-138	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2033-08-26

Cytalux Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Cytalux (pafolacianine sodium) is a targeted near-infrared fluorescent imaging agent used during surgery to identify folate receptor alpha-positive ovarian and lung cancer lesions. Its excipient strategy is commercially important because the product must preserve a fluorescent drug substance, maintain intravenous tolerability, support sterile manufacturing, and permit rapid preparation in the operating-room workflow. The principal opportunities are formulation stability, ready-to-use presentation, dose preparation, companion imaging systems, and intellectual-property protection around formulation and use.

What is Cytalux and how does its formulation work?

Cytalux contains pafolacianine sodium, a folate receptor-targeted fluorescent conjugate. The drug binds folate receptor alpha, which is expressed on many epithelial ovarian cancers and some non-small-cell lung cancers. After administration, surgeons use a compatible near-infrared imaging system to visualize lesions that may not be readily apparent under white light.

The FDA-approved product is a sterile intravenous solution concentrate. The product is diluted before administration and is used in a controlled perioperative setting rather than as a chronic therapy. That changes the excipient priorities:

• Chemical and photochemical stability during storage.
• Low particulate and low aggregate formation.
• Compatibility with dilution fluids and infusion materials.
• Minimal infusion-site and systemic tolerability risk.
• Consistent optical performance during the surgical procedure.
• Simple preparation by hospital pharmacy staff.
• Protection from light during storage and handling.

Cytalux is therefore a formulation-and-device product rather than a conventional small-molecule prescription drug. The drug product, preparation process, administration procedure, and imaging platform collectively determine commercial performance.

What excipients are used in Cytalux?

The FDA prescribing information identifies excipients used in Cytalux, including mannitol, tromethamine, polysorbate 80, hydrochloric acid, and sodium hydroxide. These components support tonicity, pH control, solubilization, and product stability. The exact quantities and manufacturing process parameters are not fully disclosed in the public label. [1]

Excipient or formulation component	Likely formulation function	Commercial and technical relevance
Mannitol	Tonicity adjustment and bulking support	May help control osmolality and improve handling of the concentrated solution
Tromethamine	Buffering and pH control	Helps maintain the pH range required for chemical and optical stability
Polysorbate 80	Surfactant and anti-adsorption agent	Can reduce surface adsorption and aggregation but requires control of oxidation and degradation products
Hydrochloric acid	pH adjustment	Supports batch-to-batch pH control
Sodium hydroxide	pH adjustment	Used to establish the final formulation pH
Water for injection	Solvent	Defines the sterile injectable vehicle and container-closure requirements

The label does not establish that each excipient independently protects the fluorescent chromophore. Product performance depends on the complete formulation, container, light exposure, oxygen exposure, concentration, pH, and sterilization or aseptic-processing conditions.

Why is excipient selection difficult for pafolacianine?

Pafolacianine combines a targeting ligand with a fluorescent component. Such conjugates can present more formulation risks than conventional small molecules because the active ingredient may be sensitive to light, oxidation, aggregation, adsorption, and changes in pH.

Photostability

Near-infrared fluorophores can lose signal after exposure to light. A practical excipient strategy must be paired with light-protective primary packaging, secondary packaging, shipping controls, and handling instructions. Excipient changes that improve chemical stability but increase light transmission or alter the local chemical environment may reduce imaging performance.

Aggregation and adsorption

Pafolacianine is a relatively large conjugated molecule compared with conventional injectable drugs. Surface interactions with glass, elastomeric components, tubing, and infusion containers can affect delivered dose. Polysorbate 80 can reduce adsorption and aggregation, but it introduces its own risks, including peroxide formation, hydrolysis, and lot-to-lot variability.

pH control

The buffer system must balance several requirements:

• Maintain chemical integrity of the conjugate.
• Preserve fluorescence intensity.
• Limit injection-site irritation.
• Prevent precipitation after dilution.
• Remain compatible with infusion solutions.
• Avoid accelerated degradation during temperature excursions.

Tromethamine provides a useful buffering platform, but a reformulated product could evaluate histidine, phosphate, citrate, acetate, or other buffer systems. Each alternative would require assessment of fluorescence, aggregation, osmolality, compatibility, and clinical tolerability.

Oxidative degradation

Fluorescent dyes and surfactants can be sensitive to oxidation. Polysorbate 80 may generate peroxide species during storage, which can affect the active ingredient. Commercial formulation development could examine low-peroxide surfactant grades, antioxidant systems, oxygen-reduced filling, nitrogen overlay, and tighter control of container-closure oxygen ingress.

Any antioxidant strategy must be validated carefully. Antioxidants can alter color, fluorescence, compatibility, or patient exposure. A formulation that improves chemical assay results but reduces intraoperative signal would not create a commercially useful product.

What formulation improvements could create commercial opportunities?

The strongest opportunities are likely to come from reducing pharmacy work, extending shelf life, improving dose consistency, and supporting broader surgical use.

Ready-to-dilute or ready-to-use presentations

Cytalux is prepared for intravenous administration in the hospital. A commercially differentiated presentation could reduce preparation steps through:

• A premeasured vial.
• A dual-chamber vial or drug-delivery system.
• A premixed infusion bag.
• A closed-system transfer device.
• A pharmacy compounding kit.
• A room-temperature-stable presentation.

A premixed product could improve handling but would face additional compatibility, shipping, microbial, and container-closure requirements. The market value would depend on whether hospitals view preparation time and dosing errors as material barriers to adoption.

Longer refrigerated or room-temperature stability

A longer shelf life could reduce wastage and improve inventory management. The product is used in scheduled surgeries, so expiration risk can affect hospital purchasing. Opportunities include:

• Improved buffer capacity.
• Lower-peroxide surfactant systems.
• Oxygen-control manufacturing.
• Light-resistant containers.
• Lyophilized or spray-dried formulations.
• More robust shipping-temperature specifications.

Lyophilization may improve stability but would add reconstitution steps, which could conflict with the operating-room value proposition. A solid formulation could also create new risks involving reconstitution time, incomplete dissolution, particle formation, and fluorescence changes.

Lower-dose or higher-concentration formulations

A higher-concentration formulation could reduce infusion volume and simplify administration. A lower-dose formulation could reduce drug cost per procedure if imaging performance remains adequate. Both strategies require clinical bridging because changes in concentration, infusion volume, exposure, or administration rate may alter safety or imaging performance.

A concentrated formulation also increases the risk of aggregation and adsorption. A lower-concentration formulation may require more volume and create a greater burden on hospital workflow.

Alternative surfactant systems

Polysorbate 80 is widely used in injectable products, but it is not the only possible surfactant. Development programs could assess:

• Polysorbate 20.
• Poloxamers.
• Polyethylene glycol-based stabilizers.
• Phospholipid systems.
• Low-peroxide surfactant grades.
• Surfactant-free formulations using optimized container surfaces.

The commercial value of a new surfactant system would be strongest if it improves long-term stability or reduces visible and subvisible particles without changing the clinical dose.

Container and delivery-system improvements

The container-closure system can be as important as the excipient composition. Relevant technologies include:

• Amber or low-light-transmission vials.
• High-barrier polymer containers.
• Low-extractable elastomeric stoppers.
• Siliconization controls.
• Low-adsorption infusion tubing.
• Light-protective transfer bags.
• Integrated dose-preparation devices.

These improvements may be protected through device, packaging, or combination-product patents rather than conventional drug-composition claims.

What patents protect Cytalux and its formulation?

Cytalux intellectual-property protection is expected to cover several layers:

1. Pafolacianine composition and chemical structure.
2. Folate receptor-targeted fluorescent conjugates.
3. Methods of detecting or resecting cancer using the agent.
4. Use in ovarian cancer surgery.
5. Use in lung cancer surgery.
6. Formulation and stability characteristics.
7. Manufacturing and purification methods.
8. Combination use with near-infrared imaging systems.
9. Dosing, timing, and administration protocols.

The public FDA label identifies the active ingredient and formulation components but does not provide a complete patent landscape. Patent analysis must distinguish issued patents from pending applications, continuation claims, terminal disclaimers, patent-term adjustments, and Orange Book-listed patents.

Orange Book status

Cytalux is an FDA-approved drug product. The Orange Book is the relevant U.S. source for any listed patents and exclusivity information. A formulation or method-of-use patent is commercially significant only if it is listed, enforceable, and relevant to the proposed generic product. [2]

The public label should not be treated as a complete statement of patent protection. Patent coverage may include claims that are not obvious from the trade name or inactive-ingredient list. Conversely, a broad patent family may provide limited practical exclusivity if its claims are narrow, expired, vulnerable to invalidity challenges, or difficult to assert against a competing product.

Patent strength of excipient claims

Excipient patents are strongest when they claim a defined combination tied to a measurable technical result, such as:

• A specific pH range.
• A defined surfactant concentration.
• A particular impurity threshold.
• A stability period under specified conditions.
• Retention of fluorescence after storage.
• Reduced aggregation or particle formation.
• Compatibility with a named container or infusion material.

A patent that merely lists conventional excipients may face greater validity and design-around risk. A claim linked to unexpected photostability or improved intraoperative signal is commercially stronger, provided the patent specification contains adequate comparative data.

When does Cytalux lose exclusivity?

Cytalux has regulatory exclusivity and patent exclusivity that must be analyzed separately.

Exclusivity category	Relevance to Cytalux
New chemical entity exclusivity	Potentially relevant to the original FDA approval, subject to the applicable approval classification
Orphan-drug exclusivity	Potentially relevant if the approved indication received orphan designation
New indication exclusivity	May apply to later-approved cancer indications if statutory criteria are met
Patent exclusivity	Depends on issued claims, expiration, patent-term adjustment, and Orange Book listing
Formulation exclusivity	Depends on formulation claims and whether they cover a competing product
Method-of-use exclusivity	Depends on whether a generic can carve out the protected indication
Regulatory exclusivity for a 505(b)(2) product	Depends on the approval route and reliance on prior findings

A precise loss-of-exclusivity date cannot be stated from the FDA label alone. The relevant date may differ by indication and patent family. FDA exclusivity listings, Orange Book records, USPTO patent data, and court records must be reconciled before modeling generic entry. [2-4]

Are generic or biosimilar challenges likely?

Cytalux is not a biologic and is not expected to face biosimilar competition. A competing product would more likely use an abbreviated new drug application, a 505(b)(2) application, or a full NDA, depending on the degree of similarity and the extent of reliance on the reference product.

Generic entry risks

A conventional ANDA applicant would need to address:

• Active-ingredient sameness.
• Pharmaceutical equivalence.
• Bioequivalence or another accepted equivalence approach.
• Sterility and injectable-product requirements.
• Formulation differences.
• Optical performance.
• Labeling and method-of-use patents.
• Device or imaging-system compatibility.

Optical imaging agents may create more regulatory complexity than ordinary injectable generics because the product's value depends on signal intensity, lesion detection, timing, and use with a compatible imaging system. FDA may require evidence that formulation changes do not materially affect imaging performance.

505(b)(2) opportunities

A 505(b)(2) pathway could support:

• A different excipient system.
• A new concentration.
• A new dosage form.
• A longer-stability product.
• A premixed infusion.
• A new administration protocol.
• A product compatible with an alternative imaging workflow.

This route could be commercially attractive if the applicant can rely partly on Cytalux's safety and efficacy findings while adding product-specific studies. Patent certifications and potential Paragraph IV litigation would remain central.

What Paragraph IV and litigation risks affect Cytalux?

A Paragraph IV challenger could argue that a listed patent is invalid, unenforceable, or not infringed. The most likely dispute categories would include:

• Obviousness of the claimed fluorescent conjugate.
• Written-description or enablement challenges.
• Anticipation by earlier folate-targeted imaging compounds.
• Non-infringement based on a different formulation or dosing schedule.
• Carve-out of a patented method of use.
• Non-infringement based on a different imaging device or surgical indication.

A formulation patent is more difficult to enforce if a competitor can preserve the same active ingredient and clinical function with a different buffer, surfactant, concentration, container, or manufacturing process.

Settlement agreements could delay generic launch, permit an authorized generic, define a licensed formulation, or establish a future entry date. Any settlement involving a Paragraph IV challenge would require review of the Federal Trade Commission's filing and public disclosure framework. [5]

No complete litigation conclusion should be drawn from the product label. Court dockets, FDA patent listings, and company disclosures must be reviewed together.

Which commercial opportunities exist beyond the current Cytalux product?

Expanded surgical indications

The same targeting mechanism may support additional folate receptor alpha-positive cancers or surgical settings. Expansion would depend on receptor expression, clinical detection benefit, surgical workflow, and reimbursement.

Potential opportunities include:

• Additional thoracic procedures.
• Metastatic disease resection.
• Peritoneal and pelvic surgery.
• Earlier-stage disease.
• Combination use with robotic or minimally invasive surgery.
• Intraoperative assessment of residual disease.

Imaging-system partnerships

Cytalux creates demand for compatible near-infrared imaging equipment. Commercial models could include:

• Drug-and-device bundled sales.
• Hospital platform agreements.
• Procedure-based pricing.
• Imaging-system leases.
• Co-development with surgical-device companies.
• Exclusive regional distribution arrangements.

The imaging system can create a practical barrier to substitution. A competing drug may need to work with existing installed equipment or secure a parallel device partnership.

Hospital pharmacy and operating-room services

A formulation with fewer preparation steps could support premium pricing if it reduces labor, wastage, and scheduling friction. Commercial opportunities include pharmacy-prepared kits, validated administration protocols, and integrated ordering systems. These are service and workflow opportunities rather than pure excipient opportunities, but they directly influence adoption.

Licensing opportunities

Potential licensing targets include:

• Fluorescent dye chemistry.
• Folate receptor ligands.
• Low-peroxide surfactant technology.
• Photoprotective packaging.
• Injectable conjugate manufacturing.
• Near-infrared imaging hardware.
• Robotic surgery platforms.
• Regional pharmaceutical distributors.

Licensing value will depend on whether the partner contributes a protected technology that improves stability, reduces cost, enables a new indication, or lowers regulatory risk.

How does Cytalux compare with other intraoperative fluorescent agents?

Cytalux competes in a specialized market that includes targeted and non-targeted fluorescent imaging agents. Its main differentiation is folate receptor alpha targeting, while other products use different receptors, dyes, or mechanisms.

Product category	Target or mechanism	Commercial implication
Cytalux	Folate receptor alpha-targeted near-infrared imaging	Focused value in receptor-positive tumors
Indocyanine green	Non-targeted fluorescent dye	Broad use, lower molecular targeting specificity
HER2-targeted imaging agents	HER2-directed tumor visualization	Potentially relevant to HER2-expressing cancers
Other investigational conjugates	Various tumor-associated targets	May compete by indication or imaging workflow

Cytalux's formulation opportunity is stronger than that of a simple dye because the conjugate must preserve both targeting and optical function. Its commercial risk is also higher because adoption depends on tumor biology, pathology confirmation, imaging equipment, surgeon training, and reimbursement.

What is the revenue exposure from formulation and excipient strategy?

Public sources do not provide a consistently reported, audited Cytalux revenue series that isolates sales by indication, formulation, or hospital account. Revenue exposure is therefore best modeled through procedure volume and net price rather than through published product-level financial statements.

A practical commercial model is:

Annual product revenue = treated procedures x utilization rate x net price per procedure

Key variables include:

• Number of eligible ovarian and lung cancer surgeries.
• Percentage of hospitals with compatible imaging systems.
• Surgeon adoption.
• Reimbursement and hospital budget treatment.
• Product wastage.
• Inventory expiration.
• Repeat use by high-volume centers.
• Expansion into additional indications.
• Competitive entry timing.

Excipient improvements affect revenue indirectly by increasing usable shelf life, reducing wastage, lowering preparation burden, and improving supply reliability. A premium ready-to-use presentation could support higher net pricing if it produces measurable hospital savings.

What is the strongest commercial excipient strategy for Cytalux?

The most defensible strategy is a stability-led reformulation that preserves the existing clinical workflow. Priority development areas are:

1. Reduce light- and oxidation-related degradation.
2. Maintain fluorescence after storage and dilution.
3. Reduce aggregation and particulate formation.
4. Improve compatibility with infusion materials.
5. Extend shelf life without increasing preparation steps.
6. Protect the formulation through composition, container, process, and use claims.
7. Develop a ready-to-dilute presentation if hospital workflow data supports it.
8. Generate comparative data against the current product for regulatory and patent purposes.

A lyophilized product could offer greater stability, but it may weaken the product's operational advantage if reconstitution becomes burdensome. A premixed infusion could improve convenience but may increase shipping, container, and stability costs. The commercially optimal product is likely the one that improves supply-chain reliability without requiring a new surgical procedure or imaging platform.

Key Takeaways

• Cytalux is a targeted fluorescent imaging product whose performance depends on active ingredient, excipients, packaging, administration, and imaging hardware.
• Its labeled excipients include mannitol, tromethamine, polysorbate 80, hydrochloric acid, and sodium hydroxide.
• The main formulation risks are photodegradation, oxidation, aggregation, adsorption, and dilution compatibility.
• The strongest excipient opportunities involve longer stability, low-peroxide surfactant systems, photoprotective packaging, and reduced pharmacy preparation.
• Cytalux is not a biosimilar product opportunity. Generic and 505(b)(2) pathways are more relevant.
• Formulation patents are strongest when tied to measurable stability, fluorescence, impurity, or particle outcomes.
• A precise patent-expiration or loss-of-exclusivity date requires reconciliation of FDA, Orange Book, USPTO, and court records.
• Commercial expansion depends on hospital adoption, compatible imaging systems, surgeon workflow, reimbursement, and additional targeted indications.

FAQs

What is the main excipient risk in Cytalux?

The principal risk is loss of product quality through light exposure, oxidation, aggregation, adsorption, or pH-related degradation. These effects can reduce delivered dose or near-infrared fluorescence.

Could Cytalux be reformulated without new clinical trials?

Some changes may qualify for a pharmaceutical equivalence or bridging strategy, but a significant change in concentration, infusion volume, excipient exposure, administration rate, or imaging performance may require additional FDA studies.

Is polysorbate 80 replaceable in Cytalux?

Potentially. Alternative surfactants or surfactant-free systems could be evaluated, but the replacement must preserve stability, fluorescence, sterility, tolerability, and compatibility with the container and infusion system.

Could a ready-to-use Cytalux product command a premium price?

Yes, if it reduces pharmacy labor, preparation errors, wastage, or procedure delays. The premium would depend on hospital economics and evidence showing a measurable workflow benefit.

What would make a competing pafolacianine product difficult to launch?

The main barriers would be active-ingredient and method-of-use patents, manufacturing complexity, optical-performance requirements, injectable-product regulation, imaging-system compatibility, and the need to demonstrate equivalent intraoperative performance.

References

1. U.S. Food and Drug Administration. (2023). Cytalux (pafolacianine sodium) injection: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. Federal Trade Commission. (2024). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act.